Scotia Widens Epogam Markets
Scotia has expanded its European market access with the signing of an exclusive marketing deal with Laboratorios Leti covering sales of Epogam (gamma linolenic acid) in Spain, and the launch of Epogam Pediatric in Germany by Scotia's German licensee Beiersdorf.
The launch in Germany is for a new snip-off capsule containing 80mg of the drug, which is intended to supplement the existing 40mg dose which has been marketed since 1990 by Beiersdorf.
The firm says that research has suggested that levels of linolenic acid metabolites in the tissues of atopic eczema sufferers were consistently low. This indicates the possibility of an abnormality in the way in which people with atopic eczema convert linoleic acid to GLA, it adds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze